Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA crosslinking, induced by carboplatin, involves the formation of covalent bonds between nucleotides, primarily through platinum-DNA adduct formation. This process disrupts DNA replication and transcription, leading to cell cycle arrest and cell death, making it a target for cancer chemotherapy.
Carboplatin enters cells, hydrolyzes to form a reactive platinum complex, and covalently binds to DNA, primarily at the N7 position of guanine and adenine bases. This forms DNA adducts, including intrastrand and interstrand crosslinks, distorting the DNA structure and inhibiting replication and transcription. This ultimately leads to cell cycle arrest and apoptosis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Crosslinking (Carboplatin-induced) (N/A).